Nick
Analyst
Barclays
Equibles does not estimate personal net worth.
About Nick
Nick is recorded as Analyst at Barclays. Nick has spoken on 1 earnings call across 1 company, most recently for Karyopharm Therapeutics Inc. on May 14, 2026. The companies whose calls Nick spoke on are classified in the Healthcare sector.
Nick on recent calls
“Just for myelofibrosis, could you discuss the gating factors for potential compendia inclusion for Selenexor? And if Selenexor is included on guidelines in the future, could you discuss how you view this opportunity versus an approval?”
Affiliation history
-
Barclays
Analyst
Transcript header (unverified)
Current